Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials | Zendy

Thomas P. Lodise | Zendy; Sam Colman | Zendy; Daniel S. Stein | Zendy; David Fitts | Zendy; Lisa Goldberg | Zendy; Elizabeth Alexander | Zendy; Patrick Scoble | Zendy; Jennifer Schranz | Zendy

Open Access

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Author(s) -

Thomas P. Lodise,

Sam Colman,

Daniel S. Stein,

David Fitts,

Lisa Goldberg,

Elizabeth Alexander,

Patrick Scoble,

Jennifer Schranz

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa145

Subject(s) - medicine , double blind , moxifloxacin , post hoc analysis , clinical trial , bacterial pneumonia , post hoc , pneumonia , intensive care medicine , antibiotics , placebo , alternative medicine , pathology , microbiology and biotechnology , biology

Time to clinical response, a proxy for hospital “discharge readiness,” was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research